Drs. Robert Ferris and Laura Chow discuss some of the practicalities involved in treating patients with HNSCC with checkpoint inhibitors.
This activity is intended for oncologists, surgeons, pathologists, and other healthcare professionals who treat patients with head and neck cancer.
The goal of this activity is to discuss the role of immunotherapy in the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) and to highlight strategies for working effectively with patients to achieve optimal care.
Approximate Time to Complete: 20 minutes
Course Available Beginning: Feb. 17, 2017
Developed through a partnership between SITC and Medscape.
Upon completion of this activity, participants will be able to:
- Have increased knowledge regarding the recent clinical evidence for the use of immune checkpoint inhibitors, particularly factors that may influence individualized treatment choices
- Have increased knowledge regarding the use of strategies to optimize patient-centered management when determining a treatment plan for patients with HNSCC